Rebecca  Jeun

Rebecca Jeun

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2025 in Immunotherapy
Verified
Journal Article
Open access
RJRebecca Jeun
Rebecca Jeun
Type 1 diabetes (T1D) is characterized by the autoimmune destruction of insulin-producing β-cells of the pancreatic islets necessitating lifelong insulin therapy. Despite significant advancements in diabetes technology with increasingly sophisticated methods of insulin delivery and glucose monitoring, people with T1D remain at risk of severe complications like hypoglycemia and diabetic ketoacidosis. There has long been an interest in altering the immune response in T1D to prevent or cure T1D across its various stages with limited efficacy. This review highlights immunomodulatory approaches over the years including the anti-CD3 monoclonal antibody teplizumab which is now approved to delay onset of T1DM and other interventions under current investigation.

22 August 2025 in Cancers
Verified
Journal Article
Open access
PDF file
AGAyush Gandhi
Ayush Gandhi
RJRebecca Jeun
Rebecca Jeun
ZWZhongya Wang
Zhongya Wang
SKSonya Khan
Sonya Khan
CBConor Best
Conor Best
STSonali Thosani
Sonali Thosani
Background/Objectives: Diabetic ketoacidosis (DKA) is a life-threatening emergency resulting in significant morbidity and health care utilization. The most common cause of DKA in the general population is insulin nonadherence, but limited data exists on precipitating factors for DKA in cancer patients. In this study, we characterize the demographic and clinical characteristics of hospitalized patients with DKA at our comprehensive cancer center. Methods: This single-center retrospective study evaluated 91 patients with 94 admissions for DKA at our institution between January 2019 and December 2021. Demographic, clinical, and biochemical data were obtained from a review of the electronic medical record. Patient characteristics were summarized using descriptive statistics for continuous variables and categorical variables. Results: Of the 91 patients, 21% of patients (n = 19) had underlying type 1 diabetes, 49% of patients (n = 45) had type 2 diabetes, and 30% of patients (n = 27) had drug-induced diabetes. A total of 39% (n = 29) had poorly controlled diabetes with HbA1c > 9% (75 mmol/mol). In patients with known type 1 diabetes, the most common provoking factors were inadequate insulin therapy and infection related causes. In patients with known type 2 diabetes or no previous history of diabetes, the most common provoking factors were medications such as immune checkpoint inhibitors, SGLT2 inhibitors and steroids. Conclusions: We characterized the precipitating factors for DKA based on patients’ underlying diabetes status. While insulin non-adherence was the most common cause in patients with known type 1 diabetes, drugs associated with cancer related treatments emerged most common precipitating factor for DKA in cancer patients with underlying type 2 diabetes or drug induced diabetes. A tailored approach with proactive counseling may be helpful in timely recognition and treatment of DKA in cancer patients.